|
(a) Cell line
|
ABT-737
|
Doxorubicin
|
ABT-737 + doxorubicin
|
CI
|
|---|
|
FTC236 (FTC))
|
96.2 ± 6.5
|
92.4 ± 4.2
|
68.4 ± 5.9
|
1.30 syn.
|
|
ML1 (FTC)
|
86.5 ± 7.3
|
75.9 ± 5.4
|
37.6 ± 1.5
|
1.75 syn.
|
|
BHT101 (PTC)
|
84.4 ± 5.5
|
90.1 ± 6.1
|
78.6 ± 6.7
|
0.97 add.
|
|
SW1736 (ATC)
|
95.6 ± 7.0
|
74.3 ± 4.8
|
34.7 ± 3.0
|
2.05 syn.
|
|
HTh7 (ATC)
|
98.6 ± 4.6
|
65.0 ± 5.5
|
62.2 ± 3.1
|
1.03 add.
|
|
(b) Cell line
|
ABT-737
|
Gemcitabine
|
ABT-737 + gemcitabine
|
CI
|
|---|
|
FTC236 (FTC)
|
99.1 ± 4.8
|
79.4 ± 4.8
|
61.3 ± 5.0
|
1.28 syn.
|
|
ML1 (FTC)
|
86.0 ± 5.3
|
83.2 ± 5.4
|
54.8 ± 3.8
|
1.31 syn.
|
|
BHT101 (PTC)
|
84.9 ± 6.9
|
87.6 ± 6.7
|
76.2 ± 5.2
|
0.98 add.
|
|
SW1736 (ATC)
|
96.8 ± 6.1
|
78.5 ± 3.8
|
56.1 ± 2.5
|
1.35 syn.
|
|
HTh7 (ATC)
|
97.3 ± 7.5
|
71.8 ± 4.2
|
42.9 ± 3.9
|
1.63 syn.
|
|
(c) Cell line
|
ABT-737
|
Cisplatin
|
ABT-737 + cisplatin
|
CI
|
|---|
|
FTC236 (FTC)
|
95.9 ± 7.9
|
102.6 ± 9.3
|
99.7 ± 7.4
|
0.99 add.
|
|
ML1 (FTC)
|
84.8 ± 5.8
|
97.3 ± 7.4
|
83.5 ± 6.9
|
0.99 add.
|
|
BHT101 (PTC)
|
83.4 ± 6.3
|
98.1 ± 8.7
|
81.7 ± 5.7
|
1.00 add.
|
|
SW1736 (ATC)
|
95.0 ± 5.6
|
103.8 ± 7.2
|
101.9 ± 6.9
|
0.97 add.
|
|
HTh7 (ATC)
|
99.3 ± 7.8
|
98.5 ± 5.9
|
100.2 ± 7.0
|
0.98 add.
|
- MTT assays were performed to determine the viability of cells after incubation with one compound alone or in combination. Cl values were calculated according to the method of Drewinko et al. [34; see “Methods” section], where Cl > 1.05 indicates synergism (syn.), 0.95 ≤ Cl ≤ 1.05 indicates additivity (add.) and Cl < 0.95 indicates antagonism
